CCM
KYMR icon

CAAS Capital Management’s Kymera Therapeutics KYMR Stock Holding History

CAAS Capital Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-169,771
Closed -$10.5M – 1286
2020
Q4 		$10.5M Buy
169,771
+144,251
+565% +$7.04M 0.1% 193
2020
Q3 		$825K Buy
+25,520
New +$779K 0.02% 356

Other funds holding KYMR

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DIC
Deer IX & Co Larchmont, New York $971M AUM 24.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

CAAS Capital Management's KYMR Position: Q1 2021 in Review

CAAS Capital Management sold out of Kymera Therapeutics (KYMR) in Q1 2021, closing a stake of 169,771 shares — an estimated $10.5M sold.

CAAS Capital Management first reported a position in KYMR in Q3 2020 and held it in 2 quarters. The position peaked at $10.5M in Q4 2020. 97 funds tracked by Wall St. Rank hold KYMR as of Q1 2021.

  • CAAS Capital Management reported no remaining Kymera Therapeutics position as of Q1 2021 after selling out during the quarter.
  • CAAS Capital Management sold 169,771 Kymera Therapeutics shares in Q1 2021, an estimated $10.5M.
  • CAAS Capital Management first reported a position in Kymera Therapeutics in Q3 2020 and held it in 2 quarters.
  • CAAS Capital Management's Kymera Therapeutics position peaked at $10.5M in Q4 2020.
  • 97 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2021.

Based on CAAS Capital Management's 13F filing for Q1 2021, filed 17 May 2021.